Urine test improves detection of alcohol use in liver transplant patients
Urine test improves detection of alcohol use in liver transplant patients
By Sharon Nirenberg MD
NEW YORK (Reuters Health) - When used together, urinary
ethyl glucuronide (uEtG) and the Alcohol Use Disorders
Identification Test for alcohol consumption (AUDIT-c) improve
the detection of alcohol consumption in liver transplant
candidates and recipients, according to a recent study.
The study, published online May 7 in Liver Transplantation,
confirms the results of previous studies which found uEtG was
the most sensitive and accurate marker of alcohol consumption
when compared to others, including carbohydrate deficient
transferrin, urinary ethanol (uETOH), and serum ethanol (sETOH).
Previous studies have also shown that uEtG can detect low
levels of alcohol (approximately 10 g) up to 80 hours after
alcohol was last consumed.
Liver transplant patients who abstain from alcohol for a
period of time prior to transplantation are less likely to
relapse post transplant, experts believe. Furthermore, alcohol
use after transplant is associated with increased morbidity and
mortality due to graft loss and noncompliance with
immunosuppressive therapy.
"It is crucial to assess alcohol consumption both in liver
transplant candidates and in liver transplant recipients,"
senior author Dr. Paolo Angeli of the University of Padova,
Italy, told Reuters Health via email. This study, he added,
shows that routine use of the AUDIT-c and uEtG, which are simple
and reliable tools, may help physicians detect alcohol
consumption in these patient populations.
Dr. Angeli and colleagues assessed the sensitivity,
specificity, and accuracy of various serum and urine markers in
determining alcohol consumption in 121 liver transplant
candidates and recipients. Additionally, a hepatologist
administered the AUDIT-c at each outpatient visit.
Alcohol consumption was detected in 32.7% of the liver
transplant candidates (32/98) and 21.7% of the recipients
(5/23). Twenty patients with a positive biomarker denied alcohol
consumption on the AUDIT-c assessment.
uEtG was the most sensitive (89.2%) and accurate (95.9%)
marker for detecting alcohol consumption. Additionally,
compared to carbohydrate deficient transferrin (CDT), uEtG was
more strongly correlated with the amount of alcohol patients
reported consuming. Together, uEtG and AUDIT-c demonstrated a
higher accuracy in detecting alcohol consumption than CDT and
AUDIT-c (AUROC=0.98 vs 0.80; p<0.001).
"We know that patients do not always tell us when they are
drinking, but it is important to find out in order to get them
back into treatment to improve posttransplant outcomes, " Dr.
Patricia A. Sheiner, a liver transplant surgeon at Hartford
Hospital in Connecticut, told Reuters Health via email.
Dr. Sheiner, who was not involved in the study, added, "The
use of the uEtG test, if inexpensive and easy to get, will gain
more traction, especially since it can detect lower levels of
alcohol used in the past 80 hours which is an improvement over
testing used today."
SOURCE: http://bit.ly/1qVVG4Q
Liver Transpl 2014.
|